Michael L. Meyers - 30 Dec 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
SVP, Chief Medical Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
30 Dec 2021
Net transactions value
+$51,743
Form type
4
Filing time
03 Jan 2022, 15:03:08 UTC
Next filing
03 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $51,743 +5,900 +38% $8.77 21,566 30 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -5,900 -100% $0.000000* 0 30 Dec 2021 Common Stock 5,900 $8.77 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is filing this Form 4 to report the acquisition of shares by the Reporting Person pursuant to the exercise of a stock option grant. There are no sales to report in this filing.
F2 This option is fully vested.